Goldman wants to repay bailout money this year

February 5, 2009 04:20


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Goldman Sachs Group Inc.'s chief financial officer said Wednesday the bank would like to pay back the $10 billion in financial rescue funds it received from the Treasury Department some time this year. Goldman Sachs received the investment last fall as part of the government's bailout program intended to encourage lending between banks and to consumers. Under the agreement, companies that receive funds through the program can repay the government with money raised from sales of new stock. Goldman's CFO David Viniar was quoted by media outlets as saying at an investor conference Wednesday that the bank would consider raising capital this year to pay back the investment. Company spokesman Ed Canaday confirmed that Viniar made the remarks.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection